Market Overview

Hapoalim Securities Expects Genzyme To Hold Out For A Higher Offer


Genzyme Corporation (NASDAQ: GENZ) used its Analyst Day to outline why it thinks the Sanofi bid is too low, but stated that it was not against a sale at an appropriate price, Hapoalim Securities reports.

“We would expect Genzyme to hold out for a higher offer and due to the limited opportunities for internal growth at Sanofi, we would also expect Sanofi to eventually make a higher bid,” Hapoalim Securities writes. “While $69 per share is obviously too low for Genzyme, $89 per share is likely too high, and we would expect the two companies to eventually meet in the middle, suggesting a final offer of approximately $79 per share or 9% above current levels.”

Genzyme Corporation closed Friday at $72.45.

Posted-In: Genzyme Corporation Hapoalim SecuritiesAnalyst Ratings


Related Articles (GENZ)

View Comments and Join the Discussion!

Latest Ratings

TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at